Oral fast release pharmaceutical compositions and methods for weight loss treatment

Abstract

The present disclosure relates to an oral pharmaceutical composition for treating multiple diseases, comprising a salt of a denatonium cation and an acid anion (collectively "denatonium salt") selected from the group consisting of acetate (DA), citrate (DC), tartrate (CT), maleate (DM), and combinations thereof, and a pharmaceutical excipient for gastric release of the denatonium salt. The present disclosure also relates to an oral fast-release pharmaceutical composition that substantially liberates an active pharmaceutical ingredient (API) in the gastric region of the gastrointestinal tract, wherein the API comprises an effective amount of denatonium salt. Preferably, the oral fast-release pharmaceutical formulation comprises about 0.5 g to about 5 g of denatonium salt, capable of delivering a daily dose of about 20 mg to about 150 mg of denatonium salt to an adult human.

Description

[Technical field]

[0001] The present disclosure provides an oral pharmaceutical composition for treating multiple diseases, comprising a salt of a denatonium cation and an acid anion (collectively "denatonium salt") selected from the group consisting of acetate (DA), citrate (DC), tartrate (CT), maleate (DM) and combinations thereof, and a pharmaceutical excipient for release of the denatonium salt in the stomach. The present disclosure further provides an oral fast release pharmaceutical composition that substantially liberates an API (active pharmaceutical ingredient) in the stomach region of the gastrointestinal tract formulation, the API comprising an effective amount of a denatonium salt. Preferably, the oral fast release pharmaceutical formulation comprises about 0.5 g to about 5 g of denatonium salt, capable of delivering a daily dose of about 20 mg to about 150 mg of denatonium salt to an adult human. [Background technology]

[0002] Chemosensory signaling by nutrients plays a role in regulating appetite, digestion, and metabolism. In particular, the diverse bitter taste receptor (TAS2R) family of G protein-coupled receptors (GPCRs) is present not only in the oral cavity but also in intestinal secretory cells, human gastric smooth muscle cells, adipocytes, and even in the chemoreceptor trigger zone in the medulla oblongata.

[0003] Obesity is a global epidemic with serious health and socioeconomic consequences for millions of adults and children (Bluher, Nat. Rev. Endocrinol. 15 (2019) 288-298). Worldwide, at least 13% of adults and 7% of children are obese, while in some countries, at least 30% of the population is obese (Ng et al. Lancet 384 (2014) 766-781).

[0004] Although diet and exercise are ideal for treating obesity, the observed success rate of such programs is low, at around 20%. In many cases, this is due to a strong appetite drive that is difficult to overcome due to the redundancy of appetite-stimulating pathways, and suppression of one appetite-stimulating pathway frequently leads to compensatory enhancement of alternative pathways, evoking hunger over time. Most of the various drugs that have been marketed have only modest efficacy, or are associated with risks and side effects that are considered unacceptable by many people, or both.

[0005] Appetite suppressants such as ephedrine, fenfluramine and dexfenfluramine have been removed from the market due to cardiovascular safety risks. Drugs that inhibit nutrient absorption, such as orlistat, a lipase inhibitor that blocks lipid processing in the intestine, can cause oily stools and diarrhea. Drugs that act on the central nervous system, such as sibutramine (a monoamine oxidase inhibitor), rimonabant (a cannabinoid receptor antagonist), etc., have significant central nervous system (CNS) off-target effects, often resulting in unintended psychiatric or neurological symptoms.

[0006] Behavioral interventions for obesity, such as exercise therapy and dietary modification, often fail, and bariatric surgery is not an option for most people. Anti-obesity drugs are effective in weight loss, but are associated with side effects ranging from headache, nausea, and dizziness to severe psychiatric disorders and cardiovascular events (MO Dietrich et al., Nat. Rev. Drug Discov. 11 (2012) 675-691). The medical, social, and economic burden of obesity is enormous, and there is an urgent need to develop new safe and effective treatments for this potentially fatal and debilitating disease.

[0007] Bitter taste receptors (TAS2R) comprise a family of multiple G protein-coupled receptors (GPCRs) that are expressed in the tongue as well as in organs such as the brain, oral cavity, lungs, pancreas, and gastrointestinal mucosa (Jaggupilli et al., Mol. Cell. Biochem. 426 (2017) 137-147).

[0008] Denatonium benzoate activates eight human TAS2Rs (TAS2R 4, 8, 10, 13, 39, 43, 46, and 47) to various degrees (Meyerhof et al., Chem. Senses 35 (2010) 157-170). In rodent models of obesity, denatonium benzoate suppressed food intake and reduced weight gain (Avau et al., PLoS One 10 (2015) e0145538; and Glendinning et al., Physiol. Behav. 93 (2008) 757-765). Furthermore, intragastric administration of denatonium benzoate in healthy subjects reduced fasting gastric motility, decreased nutrient tolerance, attenuated hunger, and increased postprandial satiety (Avau et al., Sci. Rep. 5 (2015) 15985; and Deloose et al., Am. J. Clin. Nutr. 105 (2017) 580-588). However, two studies of denatonium benzoate raised concerns about its aversive side effects. Thus, there is a strong need in the art to address obesity and its associated disorders with improved, safer bitter taste receptor agonists. The present disclosure addresses this need. Summary of the Invention

[0009] The present disclosure is based on the finding that in comparative in vivo studies, denatonium salts with acid anions have better side effects than denatonium benzoate, the only available denatonium salt and the denatonium salt reported in previous studies.

[0010] The present disclosure provides an oral pharmaceutical composition for treating multiple diseases, comprising a salt of a denatonium cation and an acid anion (collectively "denatonium salt") selected from the group consisting of acetate (DA), citrate (DC), tartrate (CT), maleate (DM) and combinations thereof, and a pharmaceutical excipient for release of the denatonium salt in the stomach. The present disclosure further provides an oral fast release pharmaceutical composition that substantially liberates an API (active pharmaceutical ingredient) in the stomach region of the gastrointestinal tract formulation, the API comprising an effective amount of a denatonium salt. Preferably, the oral fast release pharmaceutical formulation comprises about 0.5 g to about 5 g of denatonium salt, capable of delivering a daily dose of about 20 mg to about 150 mg of denatonium salt to an adult human.

[0011] The present disclosure provides an oral intragastric fast release pharmaceutical formulation ("oral formulation") containing granules comprising a salt of a denatonium cation and an acid anion (collectively "denatonium salt") selected from the group consisting of acetate (DA), citrate (DC), tartrate (CT), maleate (DM) and combinations thereof, and a pharmaceutical excipient for release of the denatonium salt in the stomach. Preferably, the pharmaceutical excipient comprises talc, cellulose, and saccharide. Preferably, the oral formulation further comprises an organic acid selected from the group consisting of acetic acid, malic acid, maleic acid, citric acid and combinations thereof. Preferably, the oral formulation further comprises about 0.5 g to about 5 g of acetic acid. Preferably, the daily dose of acetic acid for an adult is about 1.5 g to about 3 g. Preferably, the daily dose of DA for an adult is about 10 mg to about 600 mg or about 5 mg / kg to about 50 mg / kg. More preferably, the adult daily dose of DA is about 10 mg to about 200 mg. Most preferably, the adult daily dose of DA is a dose that achieves a gastrointestinal concentration of about 10 mg to about 100 mg, or about 10 ppb to about 10 ppm. In terms of sustained release or fast release, the daily dose of DA is once a day, twice a day, or three times a day.

[0012] Further, the present disclosure provides an oral sustained release pharmaceutical formulation comprising DA and acetic acid powder in sustained release cellulose-based and mannitol excipients. Preferably, the adult daily dose of DA is about 10 mg to about 600 mg. More preferably, the adult daily dose of DA is about 10 mg to about 200 mg. Most preferably, the adult daily dose of DA is a dose that achieves a gastrointestinal concentration of about 10 mg to about 100 mg, or about 10 ppb to about 10 ppm. Preferably, the oral formulation comprises about 0.01% to about 10 wt% DA and about 10% to about 90 wt% dry acetic acid powder. Preferably, the dosage of DA is about 500 nmol / kg to about 4 μmol / kg. Preferably, the dosage of DA is about 10 mg to about 50 mg in adults. In terms of release profile, the daily dose of the DA is once a day, twice a day or three times a day.

[0013] The present disclosure further provides a method for effecting weight loss, comprising administering an oral intragastric fast-release pharmaceutical formulation ("oral formulation") containing granules comprising a salt of a denatonium cation and an acid anion (collectively "denatonium salt") selected from the group consisting of acetate (DA), citrate (DC), tartrate (CT), maleate (DM) and combinations thereof, and a pharmaceutical excipient for release of the denatonium salt in the stomach. Preferably, the pharmaceutical excipient comprises talc, cellulose, and saccharide. Preferably, the oral formulation further comprises an organic acid selected from the group consisting of acetic acid, malic acid, maleic acid, citric acid and combinations thereof. Preferably, the oral formulation further comprises about 0.5 g to about 5 g of acetic acid. More preferably, the daily dose of acetic acid for an adult is about 1.5 g to about 3 g. Preferably, the daily dose of DA for an adult is about 10 mg to about 600 mg or about 5 mg / kg to about 50 mg / kg. More preferably, the adult daily dose of DA is from about 10 mg to about 200 mg. Most preferably, the adult daily dose of DA is a dose that achieves a gastrointestinal concentration of from about 10 mg to about 100 mg, or from about 10 ppb to about 10 ppm. [Brief description of the drawings]

[0014] [Figure 1] Figure 3 shows a 56-day DIO mouse weight loss study (Example 3) with weight comparisons on the indicated days, with the high dose DA group (23.1 mg / kg) showing the lowest mean weight. [Diagram 2] Figure 1 shows the results of body weight change in the 56-day experiment in Example 3. Mice administered 23.1 mg / kg DA showed the lowest body weight gain compared to the high-dose DB group. [Diagram 3] The results of serum insulin at the end of the 56-day experiment in Example 3 are shown below. Serum insulin in the 23.1 mg / kg DA group was close to the baseline value (i.e., before administration) and was significantly lower than that in the vehicle-administered group. [Figure 4] 1 shows that there was no statistical difference in serum HBA1c concentration among all experimental groups in the experiment of Example 3. [Diagram 5] 2 shows cumulative food intake over 24 hours in a single-day study in rats as described in Example 4. [Figure 6] 1 shows the mean absolute body weight change during the 56 day treatment period in DIO mice of Example 6. [Figure 7A] 1 shows the dose-mortality curve of DA in Example 7. [Figure 7B] 1 shows the dose-mortality curve of DB in Example 7. [Figure 8] 1 shows a flow diagram of drug production and formulation. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0015] The present disclosure is based on the surprising discovery that the anti-obesity effects of denatonium salts with acid anions (acetate, citrate, tartrate and maleate) in in vitro and in vivo obesity models are superior in terms of both safety and efficacy. The aim of our research was to determine the effect of denatonium salts with acid anions on food and water consumption, i.e., on weight management.

[0016] In short-term food restriction experiments, Sprague Dawley rats were administered DA at doses of 7.5, 15, 30, and 60 μmol / kg. The corresponding HEDs (human equivalent doses) were 1.2, 2.4, 4.9, and 9.7 μmol / kg, respectively. In long-term food restriction experiments, C57BL / 6NTac mice were administered DA at doses of 60 μmol / kg. The corresponding HED was 4.9 μmol / kg. By way of background, Avau et al. (Sci. Rep. (2015) 5:15985) reported that the gastric emptying rate was significantly suppressed when denatonium benzoate (DB), a salt related to DA, was administered alone at 60 μmol / kg (26.8 mg / kg) to normal C57BL / 6 mice. In another study, DB administered once daily at 60 μmol / kg (26.8 mg / kg) to C57BL / 6 DIO mice induced weight loss over a 28-day period compared to vehicle administration. According to Avau et al., DB administered at 1 μmol / kg reduced nutrient tolerance and increased satiety in healthy subjects. Thus, the formulations disclosed herein provide a dose of DA of about 500 nmol / kg to about 10 μmol / kg, or about 10 mg to about 230 mg in human adults. [Table 1] Denatonium benzoate (DB) IUPAC name: Benzyl-[2-(2,6-dimethylanilino)-2-oxoeyl]-diethylazanium benzoate Molecular formula: C 28 H 34 N 2 O 3 Molecular weight: 446.581 g / mol CAS Number: 3734-33-6 ChemSpider ID: 18392 Denatonium is usually available as denatonium benzoate (brand names: BITTERANT-b, BITTER+PLUS, Bitrex or Aversion). Denatonium is used as a bitter taster to prevent ingestion. Denatonium benzoate is used in denatured alcohol, antifreeze, nail biting prevention, fit testing for protective masking, animal repellents, liquid soaps, and shampoos. Denatonium benzoate is not believed to pose any long-term health risks.

[0017] Available therapeutics with low inherent toxicity that agonize extraoral bitter taste receptors in the gut, brain, and other sites such as adipocytes could provide a relatively safe method to selectively reduce appetite and increase satiety without the off-target CNS effects or gastrointestinal disturbances typical of other obesity treatments.

[0018] A clinical use other than obesity for the combination of an orally ingested tablet or pill containing an organic acid such as acetic acid and DA is Prader-Willi syndrome. In this disease, a key feature of the genetic disease is the constant hunger urge and lack of satiety even after eating a large meal. Therefore, the present disclosure provides a method for treating Prader-Willi syndrome (PWS), characterized by administering an anti-obesity oral formulation comprising: (a) denatonium acetate (DA); (b) an organic acid selected from the group consisting of acetic acid, malic acid, maleic acid, citric acid, and combinations thereof; and (c) a pharmaceutical excipient that promotes sustained release during passage through the gastrointestinal tract. EXAMPLES

[0019] Example 1 This example is a formulation of Denatonium Acetate / Acetic Acid Release Tablet, 44.6 mg / 500 mg. [Table 2]

[0020] Microcrystalline cellulose (Avicel PH101), denatonium acetate, PVP 30 (half amount), and mannitol are added to a 10 cubic foot V-blender and mixed for 10 minutes. The mixture is transferred to a high shear granulator and granulation is started while spraying with acetic acid (half amount) at a controlled rate of 800 g / min. After granulation, the wet granules are removed and placed in a controlled tray dryer at 50°C until the final moisture content is less than 2% w / w. The dried granules are then passed through a Fitzmill equipped with an 18 mesh screen. The milled granules are then returned to the high shear granulator and the remaining half amount of PVP 30 is added and granulated again with the remaining half amount of acetic acid. The wet granules are removed and dried at 50°C until the moisture content is less than 2% w / w. The dried granules are milled in a Fitzmill with an 18 mesh screen, then blended with magnesium stearate in a 10 cubic foot V-blender for 5 minutes, and the final blend compressed into tablets on a tablet press targeting a weight of 786.6 mg and a hardness of 10 kp (uncoated tablets).

[0021] Prepare the coating solution by dispersing dibutyl sebacate in Aquacoat ECD30 dispersion and gently mix for 1 hour. Place the plain tablets in a pan coater and spray the coating solution at a controlled rate of 80 g / min. Continue drying for 30 minutes after coating is complete.

[0022] Example 2 This example is a method for making denatonium acetate / acetic acid fast release tablets, 22.3 mg / 250 mg. [Table 3]

[0023] Microcrystalline cellulose (Avicel PH101), denatonium acetate, PVP 30 (half amount), and mannitol are added to a 10 cubic foot V-blender and mixed for 10 minutes. The mixture is transferred to a high shear granulator and granulation is started while spraying with acetic acid (half amount) at a controlled rate of 800 g / min. After granulation, the wet granules are removed and placed in a controlled tray dryer at 50°C until the final moisture content is less than 2% w / w. The dried granules are then passed through a Fitzmill equipped with an 18 mesh screen. The milled granules are then returned to the high shear granulator and the remaining half amount of PVP 30 is added and granulated again with the remaining half amount of acetic acid. The wet granules are removed and dried at 50°C until the moisture content is less than 2% w / w. The dried granules are milled in a Fitzmill with an 18 mesh screen, then blended with magnesium stearate in a 10 cubic foot V-blender for 5 minutes, and the final blend compressed in a tablet press targeting a weight of 500 mg and a hardness of 10 kp.

[0024] Example 3 This example presents an in vivo acute and chronic comparative study comparing the weight loss effects of two salts with identical cations and dissimilar anions, DA and DB (denatonium benzoate). The behavioral effects of the bitter taste receptor agonists denatonium acetate and denatonium benzoate were evaluated in a 56-day study using a diet-induced obese (DIO) mouse model. Mice were habituated in a vivarium for at least 3 days and housed in groups of 2 or 3 in heap-filtered cages maintained on a standard diet and a 12:12 light-dark cycle. The experimental period consisted of a 3-5 day acclimation period plus a 28 day experimental period and a 2-3 day post-experimental experimental period. Two DA doses, 2.9 and 23.1 mg / kg BID (3.1 and 60 μmol / kg BID), DB at 26.8 mg / kg BID, and distilled water vehicle control groups were used. Mice were used at least 12 weeks of age and at least 15 C57BL / 6NTad mice per group (low-dose DA, high-dose DA, high-dose DB and control groups). Daily macroscopic observations were performed and each mouse was weighed on days 0, 1, 4, 7, 9, 11, 14, 16, 18, 21, 23, 25, 28, 30, 32, 34, 36, 39, 41, 43, 46, 48, 50, 53 and 56. Food intake was measured on days 0, 7, 14, 21, 28, 35, 42, 49 and 56. Metabolic biomarkers (blood glucose, blood insulin, blood HbA1c) were measured at the beginning and end of the experiment. DA, DB or control distilled water was administered by oral gavage (PO) at a volume of 5 mL / kg.

[0025] The results, shown in Figures 1 to 4, show that high-dose DA showed superior weight loss to high-dose DB.

[0026] Example 4 This example is a 24-hour experiment comparing DA and DB in male Sprague Dawley, Charles River rats. Five groups of 15 rats each were gavaged with distilled water vehicle control 4 times per day, DB dose of 26.8 mg / kg 4 times per day, low dose DA of 2.9 mg / kg 1 time per day, and high dose DA of 23.1 mg / kg 1 time per day. Food intake was measured 2, 4, 6, 8, and 24 hours after dosing. Results of cumulative food intake over 24 hours are shown in Figure 5, with a significant main effect of drug treatment on cumulative food intake, with the high dose DA group showing the greatest effect.

[0027] Example 5 This example shows a method for synthesizing denatonium acetate (DA). Step 1: Synthesis of denatonium hydroxide from lidocaine Add 25 g of lidocaine, 60 ml of water and 17.5 g of benzyl chloride to the reflux apparatus while stirring and heating at 70-90 °C. Heat and stir the solution at said temperature for 24 hours and then cool to 30 °C. Remove the unreacted reagents with 3 × 10 mL of toluene. Dissolve 65 g of sodium hydroxide in 65 mL of cold water while stirring and add it to the aqueous reaction solution with stirring over a period of 3 hours. Filter the mixture, wash with some water and air dry. Recrystallize from warm chloroform or warm ethanol. [ka] [ka] Step 2: Preparation of denatonium acetate from denatonium hydroxide 10 g of denatonium hydroxide (MW: 342.475 g / mol, 0.029 mol), 20 mL of acetone and 2 g of glacial acetic acid dissolved in 15 mL of acetone are added to a reflux apparatus and the mixture is stirred and heated to 35° C. for 3 hours. It is then evaporated to dryness and recrystallized with warm acetone. [ka]

[0028] Example 6 This example compares the efficacy of DA and DB in food suppression and weight control. As background, Avau et al. (Sci. Rep. (2015) 5:15985) reported that oral administration of DB at 26.8 mg / kg to normal C57BL / 6 mice significantly suppressed gastric emptying rate. In our first in vivo experiment, 45 male SD rats (purchased from Envigo, 8-10 weeks old) were divided into three groups (15 rats per group), and the three groups were each given a single oral dose of vehicle (distilled water), 26.8 mg / kg DB, or 23.1 mg / kg DA, respectively, and the efficacy of DB and DA in reducing food intake was compared over a 24-hour observation period. [Table 4]

[0029] The mean cumulative food intake during the 24-h observation period is shown in Table 4. Administration of DB or DA reduced cumulative food intake compared to vehicle for all indicated periods. Furthermore, a greater reduction in food intake was observed with 23.1 mg / kg DA than with 26.8 mg / kg DB, even though the molar dose of DA was even lower than that of DB (57.4 μmol / kg vs. 60 μmol / kg). Thus, these data indicate that DA has a stronger efficacy than DB in reducing food intake due to its dissimilar anion.

[0030] In another published article, DB administered once daily at 26.8 mg / kg induced weight loss in C57BL / 6 diet-induced obese (DIO) mice compared to vehicle for a period of 28 days (Avau et al. 2, PLoS One. 2015;10(12):e0145538). In our second in vivo study, 45 male C57BL / 6N DIO mice (purchased from Envigo, 18 weeks old, high fat diet fed) were divided into three groups (15 mice per group) and given vehicle (distilled water), DB at 26.8 mg / kg, or DA at 23.1 mg / kg orally twice daily (BID) for a treatment period of 56 days to compare the efficacy of DB and DA in reducing food intake and controlling body weight. Briefly, food weights for each cage were recorded once a week at 0 and 24 h, and food consumption during that 24-h period was calculated. Additionally, mice were weighed three times a week (every 2 or 3 days) starting on day 0.

[0031] The average food consumption per mouse during a 24-hour period on the indicated measurement days during the treatment period is shown in Table 5. Of note, mice administered 23.1 mg / kg DA showed a nominal decrease in food consumption compared to vehicle-treated mice; this effect was seen throughout the experimental period. Decreased food consumption was also seen in mice administered 23.1 mg / kg DB (compared to vehicle-treated mice) on days 0, 7, 28, 35, 42, and 49, but not on days 14, 21, and 56. And food consumption in mice administered 23.1 mg / kg DA was less than that in mice administered 26.8 mg / kg DB on all indicated measurement days except day 42. [Table 5]

[0032] The mean absolute body weight change (grams) and normalized body weight change (% of baseline) over the 56-day treatment period in the three treatment groups are shown in FIG. [Table 6]

[0033] In all three experimental groups, high-fat diet feeding induced weight gain. However, compared with vehicle administration, administration of 26.8 mg / kg DB or 23.1 mg / kg DA resulted in less weight gain. Notably, from days 34 to 56, the weight gain in mice administered 23.1 mg / kg DA was less than that in mice administered 26.8 mg / kg DB. Based on these data, DA has a stronger efficacy than DB in not only reducing food intake but also in weight control due to its dissimilar anion.

[0034] Example 7 This example shows the maximum tolerated dose of two denatonium salts: commercially available denatonium benzoate (DB, molecular weight: 446.58 g / mol) and denatonium acetate (monohydrate) (DA, molecular weight (MW): 402.53 g / mol) synthesized under GMP conditions by Aardvark Therapeutics pursuant to a supply agreement. Sprague Dawley rats were administered the drugs and observed for 14 days. Twenty-four male Sprague Dawley (SD) rats and 24 female SD rats aged 8-10 weeks were purchased from Envigo. The DA group had four doses (120, 360, 1000, and 2000 mg / kg, single gavage) with three rats per sex, totaling six rats per dose, and the DB group had four doses (120, 360, 1000, and 2000 mg / kg, single gavage) with three rats per sex, totaling six rats. Estimated median lethal dose (LD) 50 ) is LD 50 The mortality rates of all drug doses in the two experimental groups are shown in Table 7. [Table 7]

[0035] In rats, the MTD (maximum tolerated dose) was the same for both DA and DB (360 mg / kg), but the mortality rate at 1000 mg / kg DA was lower compared to the same dose of DB (50% vs. 66.7%). Thus, these data indicate that DA is a safer drug than DB due to its dissimilar anion.

[0036] Figures 7A and 7B show dose-mortality curves for DA and DB. Estimated LD 50 The values ​​and fit parameters are shown in Table 8. Estimated LD of DA 50 is the estimated LD of DB 50 is higher than that of the other, and the fitness parameters of both are close. [Table 8]

[0037] Therefore, DA is a safer drug than DB because it has a different anion from DB.

[0038] Example 8 This example provides a 50 mg fast release granule formulation containing denatonium acetate monohydrate (DA) as the free base in an oral intragastric fast release pharmaceutical formulation. The formulation of the DA composition is shown in Table 9. [Table 9]

[0039] The formulation process diagram is shown in Figure 8.

[0040] The detailed manufacturing process is shown below.

[0041] 1. Drug layering process - drug layered pellets The drug layering process was carried out in a fluid bed granulator equipped with rotor inserts (rotor granulator). The drug solution was prepared by solubilizing Kollidon 30 and denatonium acetate in ethyl alcohol. The drug solution was sprayed tangentially onto a bed of refined sucrose (35 / 45 mesh) moving in a circular motion in the rotor granulator. The final drug-loaded pellets were then dried in the rotor granulator for 10 minutes, discharged, and sieved through a #20 mesh.

[0042] 2. Seal Coating Process - Seal Coating Pellets The seal coating dispersion was prepared by dissolving hypromellose E5 separately in a mixture of ethyl alcohol and purified water (1:1) until a clear solution was obtained. The remaining amount of ethyl alcohol was then added to the solution, followed by the addition of talc. The dispersion was mixed for 20 minutes until the talc dispersion was uniform. The drug-loaded pellets were sprayed tangentially with the seal coating dispersion to achieve a 5% weight gain. The seal coated pellets were then dried in a rotor granulator for 5 minutes, discharged, and further dried in a tray dryer or oven at 55°C for 2 hours. The seal coated pellets were then sieved through a #20 mesh.

[0043] 3. Final Mix – Denatonium Rapid Release (IR) Pellets The talc and seal coating pellets sieved through #60 mesh were mixed in a V-blender for 10 minutes and discharged. The mixed seal coating granules and denatonium IR pellets were used for encapsulation.

[0044] 4. Encapsulation – Denatonium Capsules, 50mg Denatonium IR pellets, 50 mg, were filled into size 1, opalescent hard gelatin capsules using an automatic capsule filling machine. The capsules then passed through a single-line capsule polisher and metal detector. In-process control of capsule weight and appearance was performed during the encapsulation process. Acceptable Quality Level (AQL) spot checks were performed by Quality Assurance (QA) on composite samples during the encapsulation process. Composite samples of the finished product were collected and analyzed as per release test regulations.

[0045] 5. Packaging – Capsules, 50mg – 30 pcs The 50 mg capsules were packaged in packs of 30 in 50 / 60cc white HDPE round S-line containers with 33mm white CRC caps. The containers were rolled and sealed using an induction sealer. The present invention also includes the following aspects and embodiments. [1] An oral pharmaceutical composition for treating a variety of diseases, comprising a salt of a denatonium cation and an acid anion (collectively "denatonium salt") selected from the group consisting of acetate (DA), citrate (DC), tartrate (CT), maleate (DM) and combinations thereof, and a pharmaceutical excipient for release of the denatonium salt in the stomach. [2] An oral fast-release pharmaceutical composition that substantially liberates an API (active pharmaceutical ingredient) in the stomach region of a gastrointestinal formulation, wherein the API comprises an effective amount of a denatonium salt. [3] The oral rapid release pharmaceutical formulation of [1] or [2], comprising about 0.5 g to about 5 g of denatonium salt capable of delivering a daily dose of about 20 mg to about 150 mg of denatonium salt to an adult human. [4] An oral intragastric rapid release pharmaceutical formulation ("oral formulation") comprising granules comprising a salt of a denatonium cation and an acid anion (collectively "denatonium salt") selected from the group consisting of acetate (DA), citrate (DC), tartrate (CT), maleate (DM) and combinations thereof, and a pharmaceutical excipient for release of the denatonium salt in the stomach. [5] The oral formulation of [4], wherein the pharmaceutical excipients include talc, cellulose, and saccharides. [6] The oral formulation described in [4] or [5], further comprising an organic acid selected from the group consisting of acetic acid, malic acid, maleic acid, citric acid, and combinations thereof. [7] The oral formulation according to any one of [4] to [6], further comprising about 0.5 g to about 5 g of acetic acid. [8] The oral formulation according to any one of [4] to [6], wherein the daily dose of DA for an adult is from about 10 mg to about 600 mg or from about 5 mg / kg to about 50 mg / kg. [9] The oral formulation according to any one of [4] to [6], wherein the daily dose of DA for an adult is from about 10 mg to about 200 mg.

[10] The oral formulation according to any one of [4] to [6], wherein the daily dose of DA for an adult is a dose that achieves a gastrointestinal concentration of about 10 mg to about 100 mg, or about 10 ppb to about 10 ppm.

[11] A method for producing weight loss, comprising administering an oral intragastric fast release pharmaceutical formulation ("oral formulation") containing granules comprising a salt of a denatonium cation and an acid anion (collectively "denatonium salt") selected from the group consisting of acetate (DA), citrate (DC), tartrate (CT), maleate (DM) and combinations thereof, and a pharmaceutical excipient for release of the denatonium salt in the stomach.

[12] The method of

[11] , wherein the pharmaceutical excipients include talc, cellulose, and saccharides.

[13] The method according to

[11] or

[12] , wherein the oral formulation further comprises an organic acid selected from the group consisting of acetic acid, malic acid, maleic acid, citric acid, and combinations thereof.

[14] The method according to any of

[11] to

[13] , wherein the oral formulation further contains about 0.5 g to about 5 g of acetic acid.

[15] The method according to any of

[11] to

[13] , wherein the daily dose of DA for an adult is from about 10 mg to about 600 mg or from about 5 mg / kg to about 50 mg / kg.

[16] The method according to any of

[11] to

[13] , wherein the daily dose of DA for an adult is from about 10 mg to about 200 mg.

[17] The method according to any of

[11] to

[13] , wherein the daily dose of DA for an adult is a dose that achieves a gastrointestinal concentration of about 10 mg to about 100 mg, or about 10 ppb to about 10 ppm.

Claims

1. An oral pharmaceutical composition comprising denatonium acetate (DA) and a pharmaceutical excipient for release of denatonium acetate in the stomach.

2. The oral pharmaceutical composition of claim 1, which is an oral intragastric fast release pharmaceutical formulation containing granules comprising denatonium acetate (DA) and pharmaceutical excipients for release of the denatonium salt in the stomach.

3. 3. The oral pharmaceutical composition of claim 2, wherein the pharmaceutical excipients include talc, cellulose, and saccharides.

4. 4. The oral pharmaceutical composition of claim 2 or 3, wherein the oral formulation further comprises an organic acid selected from the group consisting of acetic acid, malic acid, maleic acid, citric acid, and combinations thereof.

5. 5. The oral pharmaceutical composition of claim 2, wherein the oral formulation further comprises about 0.5 g to about 5 g of acetic acid.

6. The oral pharmaceutical composition according to any one of claims 2 to 4, wherein the daily dose of DA for an adult is from about 10 mg to about 600 mg or from about 5 mg / kg to about 50 mg / kg.

7. The oral pharmaceutical composition according to any one of claims 2 to 4, wherein the daily dose of DA for an adult is from about 10 mg to about 200 mg.

8. The oral pharmaceutical composition according to any one of claims 2 to 4, wherein the daily dose of DA for an adult is from about 10 mg to about 100 mg.

9. An oral gastric fast release pharmaceutical formulation ("oral formulation") for use in effecting weight loss, comprising granules comprising denatonium acetate (DA) and pharmaceutical excipients for release of the denatonium salt in the stomach.

10. An oral gastric fast release pharmaceutical formulation ("oral formulation") for use in the treatment of obesity, comprising granules comprising denatonium acetate (DA) and a pharmaceutical excipient for release of the denatonium salt in the stomach.

11. 11. The oral formulation of claim 9 or 10, wherein the pharmaceutical excipients include talc, cellulose, and saccharides.

12. 12. The oral formulation of any one of claims 9 to 11, wherein the oral formulation further comprises an organic acid selected from the group consisting of acetic acid, malic acid, maleic acid, citric acid, and combinations thereof.

13. 13. The oral formulation of any one of claims 9 to 12, wherein the oral formulation further comprises about 0.5 g to about 5 g of acetic acid.

14. 13. The oral formulation of any one of claims 9 to 12, wherein the daily dose of DA for an adult is from about 10 mg to about 600 mg or from about 5 mg / kg to about 50 mg / kg.

15. The oral formulation according to any one of claims 9 to 12, wherein the daily dose of DA for an adult is from about 10 mg to about 200 mg.

16. 13. The oral formulation of any one of claims 9 to 12, wherein the daily dose of DA for an adult is a dose that achieves a gastrointestinal concentration of about 10 mg to about 100 mg, or about 10 ppb to about 10 ppm.

Images